Key facts
- Kano Therapeutics’s last known valuation is $15.0M (Aug 2024).
- It has raised $7.4M across 2 recorded rounds; the latest was Seed Round ($5.0M) in Aug 2024.
- Notable investors include Metaplanet Holdings, Activate Global, Engine Ventures, ZAKA VC, VSquared Ventures — 12 tracked in total.
- Kano Therapeutics has filed 1 Form D with the SEC, most recently May 2024 ($5.0M sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Kano Therapeutics
Funding rounds
2 roundsAbout Kano Therapeutics
Developer of a biotechnological production platform intended to expand the reach of genome-editing-based therapies through the development of transformational biomaterials. The company uses DNA nanotechnology and synthetic biology to design and engineer novel gene vectors that carry genetic information, providing pharmaceutical and synthetic biology companies with gene delivery and vaccine construct knowledge.
- Industry
- Biotechnology
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2021
- Employees
- 9
- Website
- kanotherapeutics.com/
- Ownership
- Privately Held (backing)
Kano Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kano Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kano Therapeutics in its N-PORT filings yet. We sweep new filings monthly.